Sandra Holzhauer-Feeney, MD
Internal Medicine · Rifle, CONPI 1992773055
Payments from drug & device makers
Across 146 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$675
- AstraZeneca$299
- Lilly USA, LLC$197
- Biohaven Pharmaceutical Holding Company Ltd.$172
- Amgen$124
- Pfizer$111
- plus $824 from 21 others
What the payments were for
- Food & beverage$2,401100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $675 |
| AstraZeneca | 17 | $299 |
| Lilly USA, LLC | 14 | $197 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $172 |
| Amgen | 7 | $124 |
| Pfizer | 7 | $111 |
| Biohaven Pharmaceuticals, Inc. | 4 | $99 |
| Novo Nordisk | 4 | $64 |
| Medtronic(3 entities) | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 4 | $56 |
| UCB, Inc. | 2 | $54 |
| Exact Sciences | 3 | $51 |
| Pulmonx Corporation | 1 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 3 | $40 |
| Johnson & Johnson | 3 | $39 |
| GSK | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $35 |
| Merck | 2 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $34 |
| Novartis | 1 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
How this compares
$2,401 in reported general payments places this provider in the 90th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf)Adalimumab | 14 | $169,969 |
| MounjaroTirzepatide | 78 | $89,285 |
| EliquisApixaban | 90 | $82,567 |
| OzempicSemaglutide | 77 | $73,562 |
| XareltoRivaroxaban | 37 | $37,592 |
| JardianceEmpagliflozin | 43 | $36,399 |
| RybelsusSemaglutide | 15 | $27,035 |
| WegovySemaglutide | 16 | $21,921 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $20,602 |
| CreonLipase/Protease/Amylase | 16 | $19,193 |
| FarxigaDapagliflozin Propanediol | 30 | $18,536 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $16,444 |
| TrulicityDulaglutide | 14 | $12,961 |
| MyrbetriqMirabegron | 20 | $11,040 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $10,870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Creon, Fetzima, Synthroid | $675 | $197,89877 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $64 | $122,518108 claims |
| Lilly USA, LLCMounjaro, Trulicity | $197 | $102,24692 claims |
| PfizerEliquis | $111 | $82,56790 claims |
| Johnson & JohnsonXarelto | $39 | $37,59237 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $35 | $37,04650 claims |
| AstraZenecaFarxiga, Symbicort | $299 | $21,64842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Rifle
- Stanton ElziWheat Ridge$9.2M
- Jason HenryDenver$7.3M
- Kenneth CohenLakewood$4.5M
- Luke WebbColorado Springs$2.1M
- Alexis LealAurora$2M
- Mauricio WaintrubAurora$1.3M
- Steven BrodieColorado Springs$883K
- Monica GrafalsAvon$673K
- Gilad GordonBoulder$476K
- Kathryn PolovitzParker$403K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.